SCHEMBL3481708

SCHEMBL3481708

C#CCOc1ccc(C2N[C@H](C(=O)O)Cc3c2[nH]c2ccccc32)cc1

nearest known ligand 0.69

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 3/20 0.69
TSHR P16473 1/20 0.69
MAPK1 P28482 1/20 0.69
MEN1 O00255 4/20 0.59
KMT2A Q03164 4/20 0.59
ALDH1A1 P00352 3/20 0.59
ALOX12 P18054 1/20 0.59
KDM4E B2RXH2 5/20 0.57
CYP2C19 P33261 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
ALOX15 P16050 1/20 0.56
HSD17B10 Q99714 1/20 0.56
CCKBR P32239 2/20 0.54
MAPT P10636 2/20 0.51
HPGD P15428 1/20 0.51
HDAC1 Q13547 4/20 0.50
HDAC6 Q9UBN7 4/20 0.50
PDE5A O76074 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21292934 1.00 CYP2D6 (0.69) CYP2D6TSHRMAPK1MEN1KMT2A
SCHEMBL28514835 0.89 CCKBR (0.70) CYP2D6TSHRMAPK1MEN1KMT2A
SCHEMBL13568945 0.83 CYP2D6 (0.78) CYP2D6TSHRMAPK1MEN1KMT2A
SCHEMBL18254530 0.83 CYP2D6 (0.78) CYP2D6TSHRMAPK1MEN1KMT2A
SCHEMBL1921430 0.83 CYP2D6 (0.78) CYP2D6TSHRMAPK1MEN1KMT2A
SCHEMBL764194 0.82 CYP2D6 (1.00) CYP2D6TSHRMAPK1MEN1KMT2A
SCHEMBL29630317 0.82 CYP2D6 (1.00) CYP2D6TSHRMAPK1MEN1KMT2A
SCHEMBL17760630 0.82 CYP2D6 (1.00) CYP2D6TSHRMAPK1MEN1KMT2A
SCHEMBL28478851 0.82 CYP2D6 (1.00) CYP2D6TSHRMAPK1MEN1KMT2A
SCHEMBL4787100 0.82 CYP2D6 (1.00) CYP2D6TSHRMAPK1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8546421-B1 Oncogenic-RAS-signal dependent lethal compounds THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2013-10-01 US disclosed
US-20100081654-A1 Oncogenic-RAS-signal dependent lethal compounds NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2010-04-01 US disclosed
WO-2008103470-A2 ONCOGENIC-RAS-SIGNAL DEPENDENT LETHAL COMPOUNDS TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2008-08-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100081654-A1 Oncogenic-RAS-signal dependent lethal compounds HRAS, KRAS, NRAS CYP2D6 3927/4885TSHR 4164/4885MAPK1 95/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.